JPWO2021202590A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202590A5 JPWO2021202590A5 JP2022559492A JP2022559492A JPWO2021202590A5 JP WO2021202590 A5 JPWO2021202590 A5 JP WO2021202590A5 JP 2022559492 A JP2022559492 A JP 2022559492A JP 2022559492 A JP2022559492 A JP 2022559492A JP WO2021202590 A5 JPWO2021202590 A5 JP WO2021202590A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antibody
- mertk
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150082854 Mertk gene Proteins 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 101150022345 GAS6 gene Proteins 0.000 claims description 10
- 101150003695 proS gene Proteins 0.000 claims description 10
- 101150080066 proS1 gene Proteins 0.000 claims description 10
- 206010057249 Phagocytosis Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 210000001539 phagocyte Anatomy 0.000 claims description 8
- 230000008782 phagocytosis Effects 0.000 claims description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 6
- 102000000018 Chemokine CCL2 Human genes 0.000 claims description 6
- 241000282567 Macaca fascicularis Species 0.000 claims description 6
- 101100290803 Mus musculus Mertk gene Proteins 0.000 claims description 6
- 230000025194 apoptotic cell clearance Effects 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 230000026731 phosphorylation Effects 0.000 claims description 6
- 238000006366 phosphorylation reaction Methods 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000002090 Fibronectin type III Human genes 0.000 claims description 4
- 108050009401 Fibronectin type III Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 108091008611 Protein Kinase B Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 201000004569 Blindness Diseases 0.000 claims description 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 208000005400 Synovial Cyst Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002025 microglial effect Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 101000973901 Homo sapiens Tyrosine-protein kinase Mer Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000045684 human MERTK Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003070P | 2020-03-31 | 2020-03-31 | |
| US63/003,070 | 2020-03-31 | ||
| US202163165592P | 2021-03-24 | 2021-03-24 | |
| US63/165,592 | 2021-03-24 | ||
| PCT/US2021/024970 WO2021202590A1 (en) | 2020-03-31 | 2021-03-30 | Anti-mertk antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519962A JP2023519962A (ja) | 2023-05-15 |
| JPWO2021202590A5 true JPWO2021202590A5 (de) | 2024-04-10 |
Family
ID=75625652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559492A Withdrawn JP2023519962A (ja) | 2020-03-31 | 2021-03-30 | 抗ｍｅｒｔｋ抗体及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240294650A1 (de) |
| EP (1) | EP4126937A1 (de) |
| JP (1) | JP2023519962A (de) |
| CN (1) | CN116075525A (de) |
| WO (1) | WO2021202590A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195770A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| JP2022551603A (ja) | 2019-10-03 | 2022-12-12 | エータイアー ファーマ， インコーポレイテッド | 抗ｎｒｐ２抗体を含む組成物および方法 |
| WO2021119508A1 (en) | 2019-12-13 | 2021-06-17 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
| IL308123A (en) * | 2021-05-14 | 2023-12-01 | Inspirna Inc | MERTK peptides and their uses |
| CA3234409A1 (en) * | 2021-10-27 | 2023-05-04 | Luke G. BURMAN | Compositions and methods comprising anti-nrp2a antibodies |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0940468A1 (de) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Änderliches Gebiet einer humanisierter Antikörper |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (de) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper. |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| EP0625200B1 (de) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002239422B2 (en) | 2000-11-30 | 2006-12-07 | E. R. Squibb & Sons, L.L.C. | Transgenic transchromosomal rodents for making human antibodies |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003236015A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition |
| DE60336548D1 (de) | 2002-04-09 | 2011-05-12 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| BRPI0708909B8 (pt) | 2006-03-15 | 2021-05-25 | Alexion Pharma Inc | uso de um anticorpo que se liga a c5 para tratar um paciente que sofre de hemoglobinúria paroxística noturna |
| US20070292936A1 (en) | 2006-05-09 | 2007-12-20 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP3237450B1 (de) * | 2014-12-22 | 2021-03-03 | The Rockefeller University | Anti-mertk-antikörper und verwendungen davon |
| WO2019084307A1 (en) | 2017-10-26 | 2019-05-02 | Celldex Therapeutics, Inc. | ANTI-MERTK ANTIBODIES AND METHODS OF USE |
| EP3864046A1 (de) * | 2018-10-09 | 2021-08-18 | Bristol-Myers Squibb Company | Anti-mertk-antikörper zur behandlung von krebs |
| WO2020106461A2 (en) | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
| DK3930847T5 (da) * | 2019-02-26 | 2024-08-05 | Inspirna Inc | Anti-mertk-antistoffer med høj affinitet og anvendelser deraf |
| JP2022529154A (ja) * | 2019-04-19 | 2022-06-17 | ジェネンテック， インコーポレイテッド | 抗ｍｅｒｔｋ抗体及びその使用方法 |
-
2021
- 2021-03-30 CN CN202180030998.8A patent/CN116075525A/zh active Pending
- 2021-03-30 US US17/995,189 patent/US20240294650A1/en active Pending
- 2021-03-30 EP EP21720621.8A patent/EP4126937A1/de active Pending
- 2021-03-30 JP JP2022559492A patent/JP2023519962A/ja not_active Withdrawn
- 2021-03-30 WO PCT/US2021/024970 patent/WO2021202590A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022075818A5 (de) | ||
| JP2018108081A5 (de) | ||
| JP6513657B2 (ja) | Ｉｌ−１７ａ結合剤およびその用途 | |
| JP2018527887A5 (de) | ||
| JPWO2019129221A5 (de) | ||
| RU2009107494A (ru) | АНТИТЕЛА К ErbB2 | |
| JP2014509861A5 (de) | ||
| JP2013535970A5 (de) | ||
| US11261246B2 (en) | Anti-IL-22R antibodies | |
| JP2024024114A5 (de) | ||
| JP2024001073A5 (de) | ||
| JPWO2021202590A5 (de) | ||
| TW202309076A (zh) | 用於治療α-突觸核蛋白病之抗體 | |
| JPWO2018206790A5 (de) | ||
| JPWO2022044573A5 (de) | ||
| JPWO2020014617A5 (de) | ||
| CN115776897A (zh) | 具有H2L2与HCAb结构的结合蛋白 | |
| JP2019518473A5 (de) | ||
| JPWO2021119508A5 (de) | ||
| JPWO2021042019A5 (de) | ||
| JPWO2022077006A5 (de) | ||
| JPWO2019147863A5 (de) | ||
| RU2021112131A (ru) | Антитела, нацеленные на epn1 | |
| WO2024102067A1 (en) | Antigen binding protein specific for transmembrane activator and caml interactor (taci) | |
| JPWO2022013775A5 (de) |